E. Fougera & Company
60 Baylis Road
Melville
New York
11747
United States
Tel: 800-645-9833-Or-631-454-6996
Fax: 631-756-7017
Website: http://www.fougera.com/
11 articles about E. Fougera & Company
-
Sandoz Completes Acquisition of Fougera, Positioning Sandoz as #1 in Generic Dermatology Globally
7/23/2012
-
Federal Trade Commission OKs Novartis AG' $1.5 Billion Fougera Buy With Divestitures
7/17/2012
-
Novartis AG Snags Fougera for $1.5 Billion for Generic Skin Drugs
5/3/2012
-
Fougera Announces First Generic Approval of Adapalene Cream 0.1% (Rx), Equivalent to Differin(R)
7/6/2010
-
Nycomed Announces First Generic Approval of Imiquimod Cream 5% (Rx), Equivalent to Aldara(R)
2/26/2010
-
FDA Approves Fougera's Clotrimazole Cream USP 1%
9/12/2008
-
Fougera and Protherics PLC Increase DigiFab(R) Digoxin Immune Fab (Ovine) Supply Following Strong Demand
3/19/2008
-
Fougera Receives Approval For First Generic Sulfacetamide Sodium Topical Suspension USP 10% (Rx)
11/20/2006
-
Fougera First-To-Market With Metronidazole Topical Gel USP 0.75% (Rx)
6/6/2006
-
Fougera First-To-Market With Metronidazole Lotion 0.75% (Rx)
5/24/2006
-
Fougera Introduces The First Unit-Of-Use Delivery System For Mupirocin Ointment USP 2% (Rx)
12/1/2005